DK0415522T3 - Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat - Google Patents

Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat

Info

Publication number
DK0415522T3
DK0415522T3 DK90307044.9T DK90307044T DK0415522T3 DK 0415522 T3 DK0415522 T3 DK 0415522T3 DK 90307044 T DK90307044 T DK 90307044T DK 0415522 T3 DK0415522 T3 DK 0415522T3
Authority
DK
Denmark
Prior art keywords
reducing
hydrochloride dihydrate
ondansetron hydrochloride
crystal size
size
Prior art date
Application number
DK90307044.9T
Other languages
English (en)
Inventor
David Trevor Collin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0415522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0415522T3 publication Critical patent/DK0415522T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Otolaryngology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Glass Compositions (AREA)
DK90307044.9T 1989-06-28 1990-06-27 Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat DK0415522T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (1)

Publication Number Publication Date
DK0415522T3 true DK0415522T3 (da) 1994-09-19

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90307044.9T DK0415522T3 (da) 1989-06-28 1990-06-27 Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat

Country Status (20)

Country Link
US (1) US5622720A (da)
EP (1) EP0415522B1 (da)
JP (1) JP3093242B2 (da)
KR (1) KR0182789B1 (da)
AT (1) ATE110380T1 (da)
AU (1) AU637110B2 (da)
CA (1) CA2019944C (da)
DE (1) DE69011786T2 (da)
DK (1) DK0415522T3 (da)
ES (1) ES2060045T3 (da)
GB (1) GB8914804D0 (da)
HK (1) HK44495A (da)
HU (1) HU208009B (da)
IE (1) IE64715B1 (da)
IL (1) IL94888A (da)
NZ (1) NZ234267A (da)
RU (1) RU2002745C1 (da)
SA (1) SA90110025B1 (da)
UA (1) UA18249A (da)
ZA (1) ZA905002B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) * 2001-03-12 2002-07-27 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и метацин
MXPA04007995A (es) * 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
MXPA04010846A (es) * 2002-04-29 2005-01-25 Biogal Gyogyszergyar Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101123946B (zh) * 2005-02-23 2013-06-26 泰华制药工业有限公司 改良含量均匀度的雷沙吉兰制剂
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
CA2666512C (en) * 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
JP2608078B2 (ja) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド 医 薬
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
HK44495A (en) 1995-03-31
HU208009B (en) 1993-07-28
IE902333A1 (en) 1991-01-16
EP0415522A1 (en) 1991-03-06
UA18249A (uk) 1997-12-25
RU2002745C1 (ru) 1993-11-15
DE69011786T2 (de) 1994-12-15
CA2019944C (en) 2000-05-09
KR0182789B1 (ko) 1999-10-15
US5622720A (en) 1997-04-22
CA2019944A1 (en) 1990-12-28
EP0415522B1 (en) 1994-08-24
KR910000709A (ko) 1991-01-30
AU5787490A (en) 1991-01-03
HUT54140A (en) 1991-01-28
NZ234267A (en) 1992-11-25
AU637110B2 (en) 1993-05-20
ATE110380T1 (de) 1994-09-15
IE902333L (en) 1990-12-28
ES2060045T3 (es) 1994-11-16
JPH0395178A (ja) 1991-04-19
HU904015D0 (en) 1990-12-28
IL94888A (en) 1995-03-15
JP3093242B2 (ja) 2000-10-03
GB8914804D0 (en) 1989-08-16
SA90110025B1 (ar) 2001-03-24
ZA905002B (en) 1991-12-24
IL94888A0 (en) 1991-04-15
DE69011786D1 (de) 1994-09-29
IE64715B1 (en) 1995-08-23

Similar Documents

Publication Publication Date Title
DE69011786D1 (de) Verfahren zur Verringerung der Kristallgrösse von Ondansetron-hydrochlorid-dihydrat.
FR2669635B1 (fr) Procede de fabrication d'hydroxymethylfurfural (hmf) du purete elevee.
PT73259A (en) Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
ES2023509B3 (es) Producto granular (i).
RU92016490A (ru) Новые 2-сахаринилметил(арил и арокси)ацетаты, применимые в качестве ингибиторов протеолитических ферментов, их композиции и способ их применения
DE68917003D1 (de) Verfahren zur Herstellung von Halbleiterbauelementen, die gegen Musterverunreinigungen geschützt sind.
ZA922504B (en) Novel 2-spirocyclopropyl 4-acylcephems and processes for the preparation thereof
DE3783070D1 (en) Phenylharnstoffe.
ZA918282B (en) Derivatives of(p.substituted phenyl)oxybutane amines,their processes of production and the pharmaceutical compositions containing them
DK0533610T3 (da) Anlæg og fremgangsmåde til at producere cyanursyre
JPS525700A (en) The process for production of silicon nitride
JPS51122095A (en) A process for preparing imidazobenzenediazepine derivatives
JPS5240287A (en) Sequence controller
JPS51123064A (en) Forming process of bonding-pad area
JPS5225388A (en) Apparatus for changing the direction of goods being conveyed
JPS5277593A (en) Temperature compensating circuit of semiconductor strain meter
JPS5293787A (en) Novel process for preparation of cephem derivatives
JPS51120302A (en) Process for controlling turbine
DE3576498D1 (de) 2-sulfamoyl-1h-indole-derivate zur behandlung von hohem intraocularem druck.
MY8600520A (en) N-aryl-n (1,4,5,6-tetrahydropyrimidin-2-yl) or (4,5,6,7-tetrahydro-1-h-1,3-diazepin-2-yl) ureas for intestinal disorders and as antihypertensives
JPS5432483A (en) 8-chloro-1-methylcalbostyril and bactericide containing the same as active agent for rice plant
JPS53147186A (en) On off controller
JPS51125219A (en) Process for preparation of 2- (silylamino)alkanenitrile
JPS5272128A (en) Bias magnetic field controlling method for magnetic bubbling
JPS5352379A (en) Production of dielectric isolated ic substrate